EVOFEM BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Evofem Biosciences, Inc. – EVFM
Contacts
Kahn Swick & Foti, LLC
Managing Partner
Lewis S. Kahn
lewis.kahn@ksfcounsel.com
855-768-1857
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Evofem Biosciences, Inc. (OTC: EVFM) to Aditxt, Inc. (NasdaqCM: ADTX) in consideration of the issuance of a combination of common stock and preferred stock, and the assumption of certain senior indebtedness, having an aggregate amount of approximately $100 million. KSF is seeking to determine whether the merger and the process that led to it are adequate and fair to the Company’s shareholders.
If you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/otc-evfm/ to learn more.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231218056190/en/
Related news for (EVFM)
- FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences’ “One and Done” Oral Treatment for Bacterial Vaginosis and Trichomoniasis
- Evofem Biosciences to Present at Emerging Growth Conference
- Windtree Therapeutics Strikes Deal to Source PHEXXI, Signaling Revenue-Driven Pivot
- Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
- Evofem Biosciences Announces Financial Results for the Second Quarter of 2024